Pseudomonas aeruginosa NfsB and nitro-CBI-DEI - a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Green, Laura K ^a   Syddall, Sophie P ^b   Carlin, Kendall M ^b   Bell, Glenn D ^b   Guise, Christopher P ^b,c   Mowday, Alexandra M ^b   Hay, Michael P ^b,c   Smaill, Jeffrey B ^b,c   Patterson, Adam V ^b,c   Ackerley, David F ^a,c  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bystander effect; CB1954; GDEPT; Gene therapy; Nitro CBI DEI; Nitroaromatic prodrug; Nitroreductase; SOS chromotest

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; NITRO CHLOROMETHYLBENZINDOLINE 5 [(DIMETHYLAMINO)ETHOXY]INDOLE; NITROREDUCTASE; NITROREDUCTASE NFSA; NITROREDUCTASE NFSB; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG POTENCY; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PSEUDOMONAS AERUGINOSA;

BYSTANDER EFFECT; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME THERAPY; GENE EXPRESSION; GENETIC THERAPY; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; NITROREDUCTASES; PRODRUGS; PSEUDOMONAS AERUGINOSA; TUMOR STEM CELL ASSAY;

ESCHERICHIA COLI; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 84878693344     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-58     Document Type: Article

References (14)

1. Denny WA. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest 2004, 22:604-619. 10.1081/CNV-200027148, 15565818.
2. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000, 7:1738-1743. 10.1038/sj.gt.3301286, 11083495.
3. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 2002, 62:1425-1432.
4. Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Ther 2007, 14:953-967. 10.1038/sj.cgt.7701088, 17975564.
5. Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res 2008, 68:7995-8003. 10.1158/0008-5472.CAN-08-1698, 2596930, 18829557.
6. Prosser GA, Copp JN, Mowday AM, Guise CP, Syddall SP, Williams EM, Horvat CN, Swe PM, Ashoorzadeh A, Denny WA, Smaill JB, Patterson AV, Ackerley DF. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochem Pharmacol 2013, 85:1091-1103. 10.1016/j.bcp.2013.01.029, 23399641.
7. Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007, 167:625-636. 10.1667/RR0807.1, 17523848.
8. Swe PM, Copp JN, Green LK, Guise CP, Mowday AM, Smaill JB, Patterson AV, Ackerley DF. Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954. Biochem Pharmacol 2012, 84:775-783. 10.1016/j.bcp.2012.07.002, 22796568.
9. Tercel M, Atwell GJ, Yang S, Ashoorzadeh A, Stevenson RJ, Botting KJ, Gu Y, Mehta SY, Denny WA, Wilson WR, Pruijn FB. Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. Angew Chem Int Ed Engl 2011, 50:2606-2609. 10.1002/anie.201004456, 21370347.
10. Boger DL, Johnson DS. CC-1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies. Angew Chem Int Ed Engl 1996, 35:1438-1474.
11. Ghosh N, Sheldrake HM, Searcey M, Pors K. Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products. Curr Top Med Chem 2009, 9:494-524.
12. Wilson WR, Stribbling SM, Pruijn FB, Syddall SP, Patterson AV, Liyanage HDS, Smith E, Botting KJ, Tercel M. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators. Mol Cancer Ther 2009, 8:2903-2913. 10.1158/1535-7163.MCT-09-0571, 19808982.
13. Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol 2010, 79:678-687. 10.1016/j.bcp.2009.10.008, 19852945.
14. Winsor GL, Lam DK, Fleming L, Lo R, Whiteside MD, Yu NY, Hancock RE, Brinkman FS. Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res 2011, 39:D596-D600. 10.1093/nar/gkq869, 3013766, 20929876.